Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: Experience with fifty-four perinatally infected children

Pediatric Infectious Disease Journal

Volumn 18, Issue 6, 1999, Pages 512-516

  Purswani, Murli ^a   Johann Liang, Rosemary ^a   Cervia, Joseph ^a   Noel, Gary J ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy; Human immunodeficiency virus; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PERINATAL INFECTION; PRIORITY JOURNAL; RNA ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0033059776     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199906000-00007     Document Type: Article

References (25)

1. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, and viral generation time. Science 1996;271:1582-5.
2. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996;124:984-94.
3. Lange JMA. Current problems and the future of antiretroviral drug trials. Science 1997;276:548-50.
4. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in the plasma. Science 1997;272:1167-70.
5. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
6. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1 -infected children. J Infect Dis 1997;175: 1029-38.
7. + lymphocyte count in HIV-infected infants and children. JAMA 1998;279: 756-61.
8. Valentine ME, Jackson CR, Vavro C, et al. Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J 1998;17:18-23.
9. Centers for Disease Control (CDC). Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR 1998;47(RR-4):15-26.
10. James JS. Major pediatric study stopped early: combination treatment better (AIDS Clinical Trials Group 300). AIDS Treat News 1997;274:5-6.
11. Kline MW, Fletcher CV, Brundage RC, et al. Combination therapy including soft gelatin capsules in HIV-infected children [Abstract 229]. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998.
12. Mueller BU, Nelson RP, Sleasman J, et al. A Phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998;101: 335-43.
13. Yogev R, Stanley K, Nachman SA, Pelton S, McIntosh K, Wiznia A. Virologic efficacy of ZDV + 3TC vs. d4T + ritonavir (RTV) vs. ZDV + 3TC + RTV CTG in stable antiretroviral experienced HIV-infected children (Pediatric ACTG Trial 338). In: Program and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28 to October 1, 1997.
14. Gersten M, Peterson AK, Hendricks A, et al. A comparison of the safety and efficacy of Viracept (nelfinavir mesylate) in HIV-infected children and adults. In: Sixth European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, Germany, October 11 to 15, 1997.
15. Dobroszycki J, Rosenber M, Lambert G, et al. The effects of HAART in a group of HIV-infected infants. In: 35th Annual Meeting of the Infectious Disease Society of America, San Francisco, September 13 to 16, 1997.
16. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
17. Hammer SM, Squires KE, Hughes MD, et al. A Controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
18. Palumbo PE, Kwok S, Waters S, et al. Viral measurement by polymerase chain reaction-based assays in human immuno-deficiency virus-infected infants. J Pediatr 1995;126:592-5.
19. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immuno-deficiency virus type 1. N Engl J Med 1997;336:1337-42.
20. McIntosh K, Shevitz A, Zakhun D, et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatric Infect Dis J 1996;15:1087-91.
21. Shacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-20.
22. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents: US Department of Health and Human Services. MMWR 1998;47(RR-5):21-35.
23. Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998;352: 199-200.
24. Antiretroviral therapy and medical management of pediatric HIV infection. Pediatrics (Suppl) 1998;102:1005-62
25. Centers for Disease Control. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-12)1-10.